Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Firm's Schiff Move Free joint supplement sales fell 2.9% in the first quarter versus the prior year period which is "unacceptable, but does indicate we are starting to stabilize the brand," CEO Bruce Wood comments in Sept. 25 earnings call. In March, Weider implemented a brand-building initiative for Move Free that included over $12 mil. in ad spending to spur its sales (1"The Tan Sheet" Aug. 18, 2003, p. 13). Wood expects low, single-digit Move Free growth in Weider's 2004 fiscal year, driven by double-digit growth at year-end. The exec also says Weider plans to launch new products "branching into new broad human condition areas, an example being cardiovascular health," in 2005...

You may also be interested in...

Weider Move Free Advertising Strategy Key To Earnings Improvement

Weider says a recently launched brand-building initiative for its Schiff division's Move Free joint supplement product line will help return the company to positive earnings in the coming year

Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU

Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.

Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US

Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts